Ganetespib (STA-9090)

For research use only.

Catalog No.S1159

40 publications

Ganetespib (STA-9090) Chemical Structure

CAS No. 888216-25-9

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 302 In stock
USD 270 In stock
USD 370 In stock
USD 1070 In stock
USD 2470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Ganetespib (STA-9090) has been cited by 40 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1975 M2G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPnOm1oPzJiaB?= NF[4VVVKSzVyPUigcm0> M1PCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUS0OlY2Lz5{MkG0OFY3PTxxYU6=
NCI-H1975 M1G1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq2bI5RPDhiaB?= MkKzTWM2OD1zNjDuUS=> MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNES2OlUoRjJ{MUS0OlY2RC:jPh?=
Calu-6 NEfjeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rqVmlEPTB;NkSgcm0> NWXsbmE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
Calu-1 NHHkUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz0TWM2OD13ODDuUS=> M4HkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H2122 MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTV|IH7N Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
A549 NHvCclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jaOGlEPTB;NEOgcm0> M3OxOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H358 NVjRXpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fuS2lEPTB;Mkmgcm0> NG\DWIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1734 NF\kVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ6IH7N M3fXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
H727 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LXcWlEPTB;Mkigcm0> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
COR-L23 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrjb3RXUUN3ME2yNkBvVQ>? NWDQb4x7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H1792 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7tU3BKSzVyPUKwJI5O MonPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H2009 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCwTG9QUUN3ME2xPUBvVQ>? M4m0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
SK-LU-1 M3ryZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILrZ5NKSzVyPUG4JI5O MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMkK0PEc,OjNyMUKyOFg9N2F-
H2212 NIfpb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDnUXlKSzVyPUG3JI5O Mm\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H441 NVvQUIpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6TWM2OD1zNDDuUS=> NYLJfWNLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVIzPDhpPkKzNFEzOjR6PD;hQi=>
H2030 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF{IH7N MlPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H23 NXq3UYh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rtO2lEPTB;MUGgcm0> M4WyOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
HOP-62 M{njbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\6b5VKSzVyPUGxJI5O MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
IA-LM NVO5cHVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHMVnVKSzVyPUGwJI5O NH\DPYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H460 M{jHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRThibl2= MoTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUKyOFgoRjJ|MEGyNlQ5RC:jPh?=
H157 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37SOmlEPTB;NzDuUS=> NHjaSoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNlI1QCd-MkOwNVIzPDh:L3G+
H1355 NGmxeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXTTWM2OD13IH7N M33LflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MEGyNlQ5Lz5{M{CxNlI1QDxxYU6=
VCaP MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TOWmlEPTB;NzDuUS=> M4TpWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUWyNFA1Lz5{M{G1NlAxPDxxYU6=
LNCaP NF7KRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K2VmlEPTB;ODDuUS=> M4jGSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUWyNFA1Lz5{M{G1NlAxPDxxYU6=
Ramos-RA1 NFz3fmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDKNIlnUUN3ME23MlQhdk1? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
Karpas-299 NFzXTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n0VGlEPTB;OT62JI5O NF;6NVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
Kasumi-1 M363eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXlPFlQUUN3ME21Mlghdk1? M33FNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
CCRF-CEM (2) MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\JcY5KSzVyPUeuNkBvVQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
CCRF-CEM (1) M3n0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnBb2tKSzVyPUGyMlUhdk1? NHzobY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
MOLT-4 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjpXJBIUUN3ME2xNE43KG6P MmKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
RS4;11 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jpTGlEPTB;MUOuOUBvVQ>? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
COG-LL-317 M4fM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTRwNDDuUS=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
NALM-6 MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\oUIhKSzVyPUGxMlchdk1? NVjvflhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
CHLA-136 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ|LkKgcm0> NYfi[|d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
CHLA-90 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULXS2s6UUN3ME2yNk4{KG6P MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyM{e0NUc,OjN|MEO3OFE9N2F-
NB-EBc1 NWXLe|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF4Lkigcm0> NHHIdZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
NB-1643 NIfhdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DoN2lEPTB;Nz60JI5O NGfxcJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
SJ-GBM2 MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnzcIVKSzVyPUGyMlkhdk1? NGTFRmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwN|c1OSd-MkOzNFM4PDF:L3G+
CHLA-258 M1zESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXsTWM2OD14LkSgcm0> Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-10 NV;Hc5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PUfWlEPTB;NT63JI5O MoPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-9 NU\XXnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13UbWlEPTB;ND62JI5O NWPrV3B2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
TC-71 NXTzT41GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\6SmlEPTB;ND61JI5O MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
CHLA-266 M2P3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS3TWM2OD1{Nz6xJI5O M3LSdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{CzO|QyLz5{M{OwN|c1OTxxYU6=
BT-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF2LkOgcm0> MofpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
Rh30 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT5fXNNUUN3ME21MlYhdk1? NWPk[oVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
Rh18 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjocYVKSzVyPU[uNkBvVQ>? NXi5XFJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
Rh41 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HvWmlEPTB;MUCuOEBvVQ>? MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MEO3OFEoRjJ|M{CzO|QyRC:jPh?=
RD NFfNUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPRTWM2OD16IH7N NYS2fFJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFM4PDFpPkKzN|A{PzRzPD;hQi=>
K033 NFi1[m9CeG:ydH;zbZMhSXO|YYm= NIPVe|AyODBibl2= MXe3NkBp NEGxSnh{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NYLodHd5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
M23 MnzIRZBweHSxc3nzJGF{e2G7 NEHIWYYyODBibl2= MUm3NkBp MlX6d4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K029 M2DaUWFxd3C2b4Ppd{BCe3OjeR?= NGCw[lUyODBibl2= M4\6eFczKGh? MWXzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ NHrtO4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
K028 NFvEe5JCeG:ydH;zbZMhSXO|YYm= MkLUNVAxKG6P NV7LbWhjPzJiaB?= NYC0bnd{e2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= NW\F[VBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
K008 M1fLbGFxd3C2b4Ppd{BCe3OjeR?= NGrVclcyODBibl2= MUS3NkBp NVzCNYp4e2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzOEWyN{c,OjN2MUi1NlM9N2F-
K033 M2PucmZ2dmO2aX;uJGF{e2G7 M3PXdFI2OCCwTR?= MnHzNlQhcA>? MXfpcoR2[2W|IHGgcY9l\XO2IHnuZ5Jm[XOnIHnuJGcyKHCxcIXsZZRqd25? M4LoXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
M23 Ml25SpVv[3Srb36gRZN{[Xl? MVOyOVAhdk1? NVOzUVgyOjRiaB?= MnntbY5lfWOnczDHNUBidmRiR{KvUUBienKnc4S= MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K029 NYC4ZVVQTnWwY4Tpc44hSXO|YYm= MWWyOVAhdk1? NWPLWZNEOjRiaB?= Mn7rbY5lfWOnczDHNUBienKnc4S= M4HvV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K028 MWDGeY5kfGmxbjDBd5NigQ>? NVrMSpNCOjVyIH7N M1Ptb|I1KGh? MYXpcoR2[2W|IFeyJIFzemW|dB?= MmfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K008 NH3YeYVHfW6ldHnvckBCe3OjeR?= MXOyOVAhdk1? NEPYTYQzPCCq MWHpcoR2[2W|IFeyJIFzemW|dB?= MmPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K033 Mn3pR4VtdCCYaXHibYxqfHliQYPzZZk> Mo\6TWM2OD15NT61JI5O NVnvcm5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
M23 M1jHbWNmdGxiVnnhZoltcXS7IFHzd4F6 MVjJR|UxRTN5LkWgcm0> MlXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUi1NlMoRjJ|NEG4OVI{RC:jPh?=
K029 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MorlTWM2OD12NjDuUS=> NXLKbVZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVg2OjNpPkKzOFE5PTJ|PD;hQi=>
K028 M2f2dmNmdGxiVnnhZoltcXS7IFHzd4F6 MmnqTWM2OD16NDDuUS=> M1\lUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEG4OVI{Lz5{M{SxPFUzOzxxYU6=
K008 MkC4R4VtdCCYaXHibYxqfHliQYPzZZk> M1rvcmlEPTB;NkCgcm0> NH7oNVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxPFUzOyd-MkO0NVg2OjN:L3G+
H3122 MnrIR4VtdCCYaXHibYxqfHliQYPzZZk> NVi1V|RlOC1zMECwJI5O NVPYdnhbPzJiaB?= MWjJR|UxRTFyIH7N NGXISmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WzN|I3PSd-MkO1N|MzPjV:L3G+
H2228 NE\vZ41E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUjhZW5lOC1zMECwJI5O MWq3NkBp MXTJR|UxRTF|IH7N NYLoN4RERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N|MzPjVpPkKzOVM{OjZ3PD;hQi=>
A1847 NG[3eXlCeG:ydH;zbZMhSXO|YYm= NYXsWlNVOTBvMUCwJI5O NWjrTmZMOjRxNEivO|IhcA>? NGr5O3dqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN|YoRjJ|OUCwNVM3RC:jPh?=
OVCAR-8 NIXifopCeG:ydH;zbZMhSXO|YYm= NVvx[FlWOTBvMUCwJI5O NFLGNpMzPC92OD:3NkBp NXPFVHF5cW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> NV62bHJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
OVCAR-5 MYDBdI9xfG:|aYOgRZN{[Xl? NWPSSXZxOTBvMUCwJI5O NGXsfJQzPC92OD:3NkBp MnH1bY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= M1nDN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
SKOV-3 MlfvR4VtdCCYaXHibYxqfHliQYPzZZk> M{HPR|AuOTByMDDuUS=> M4HmXVczKGh? M1vhWolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NUT6VZNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NFAyOzZpPkKzPVAxOTN4PD;hQi=>
A1847 NUHNVJdzS2WubDDWbYFjcWyrdImgRZN{[Xl? NXmxbpVpOC1zMECwJI5O MV:3NkBp M2jIfYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMEGzOkc,OjN7MECxN|Y9N2F-
OVCAR-8 NGfGe4RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVGwMVExODBibl2= NYD3UWg6PzJiaB?= NV7HZ5QxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3HX[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUCwNVM3Lz5{M{mwNFE{PjxxYU6=
OVCAR-5 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX3VbZNrOC1zMECwJI5O NYPsdVJrPzJiaB?= MV\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MECxN|YoRjJ|OUCwNVM3RC:jPh?=
H146  NHfBSIdHfW6ldHnvckBCe3OjeR?= NHTveoc{OCCwTR?= MlS5O|IhcA>? M2\Obolv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> NFrWRYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
GLC4 NYWxfolOTnWwY4Tpc44hSXO|YYm= NEPO[JY{OCCwTR?= NGLYXYU4OiCq M4PNOolv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H82 MYnGeY5kfGmxbjDBd5NigQ>? NE[xfGg{OCCwTR?= MnfZO|IhcA>? M1PwVYlv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> NYC0dJVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
AC3 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP3ZW5KSzVyPUK1Mlkhdk1? Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H1173 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfRXHZFUUN3ME2xNk43OiCwTR?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H792 NWnVSIFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrGTWM2OD12NT6wO{BvVQ>? NYHTV3RtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H620 NFHaWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\pSllKSzVyPUOyMlY4KG6P M4PNUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MU[2OVA2Lz5{NEG2OlUxPTxxYU6=
N592 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HTfmlEPTB;MUSuNVIhdk1? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4NkWwOUc,OjRzNk[1NFU9N2F-
H526 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK5RnlJUUN3ME2yNU43PCCwTR?= NWO2RpNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H187 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ2Lkm5JI5O MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H146 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP6SXE5UUN3ME2yPE42OSCwTR?= MnfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H128 NUTocXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZ7LkW1JI5O MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNk[1NFUoRjJ2MU[2OVA2RC:jPh?=
H69 M{fQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;HeWdHUUN3ME24N{4{PiCwTR?= NH[0NpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG2OlUxPSd-MkSxOlY2ODV:L3G+
GLC4 NFzzO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i1WGlEPTB;MkCuOFchdk1? NXXofIJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
H82 M{XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH2T2ZmUUN3ME2zNE4zPyCwTR?= NUnIbHNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlY2ODVpPkK0NVY3PTB3PD;hQi=>
MDA-MB-231 M17xU2Z2dmO2aX;uJGF{e2G7 MXuxNFAhdk1? M3qz[FI1KGh? MYXpcohq[mm2czD0bIUhdWmpcnH0c5J6KGGwZDDpcpZie2m4ZTDjZZBi[2m2edMg NH7kbmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3N|U1OSd-MkSxO|M2PDF:L3G+
BT-20  MkHwSpVv[3Srb36gRZN{[Xl? MUWxNFAwOjVyIH7N NUTl[40yOjRiaB?= Mnj1doV{fWy2ZXSgbY4h[SCmb4PlMYRmeGWwZHXueEBl\XO2YXLpcIl7[XSrb36gc4YhTUeIUjygTWdHNUmULDDNSXQtKGGwZDDDVmFH NWfQXpdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|M2PDFpPkK0NVc{PTRzPD;hQi=>
MDA-MB-435 NV:zNXp5TnWwY4Tpc44hSXO|YYm= MVWxNFAhdk1? MV[zNEBucW5? NE\4WJJqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gTGlHNTIQsR?= MlT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NEiyOlUoRjJ2MkS4NlY2RC:jPh?=
MDA-MB-231 MnPsSpVv[3Srb36gRZN{[Xl? MkLqNVAxKG6P MYmzNEBucW5? MYLpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>? NEe5b2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0PFI3PSd-MkSyOFgzPjV:L3G+
HCC2998 NYDobVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7XO|M{UUN3ME2xNlghdk1? MnLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
SK-CO-1 NFXpXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvuTWM2OD16MTDuUS=> MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
LS-123 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz0bldsUUN3ME23N{BvVQ>? MkfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
SNU-C2B M2PQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDGTlRKSzVyPUS1JI5O MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
LS-1034 M4frc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH3VIUzUUN3ME2zNUBvVQ>? NFe3N4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LoVo NFvmVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfj[JM5UUN3ME2yNkBvVQ>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
COLO-678 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfsW3BKSzVyPUKxJI5O MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
NCI-H747 M3HZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS2d2h[UUN3ME2xO{BvVQ>? Ml7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
COLO-205 NFS1RXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF2IH7N M1jBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT 116 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnMXWxKSzVyPUG0JI5O NXnSbGxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PFI4PDdpPkK0OlgzPzR5PD;hQi=>
HuTu-80 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnmNHZKSzVyPUGzJI5O M4HhNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkiyO|Q4Lz5{NE[4Nlc1PzxxYU6=
HCT-15 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7tTm5KSzVyPUigcm0> MkDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OEK3OFcoRjJ2NkiyO|Q4RC:jPh?=
SW620 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLqb|dKSzVyPUigcm0> NITKe489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
LS-411 N M4\GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqwZotKSzVyPUWgcm0> NIfYSpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[4Nlc1Pyd-MkS2PFI4PDd:L3G+
RKO MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLBTIw4UUN3ME20JI5O MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6Mke0O{c,OjR4OEK3OFc9N2F-
SW780 NIW0W|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTjTWM2OD1|NEWxJI5O NGHWclg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
RT4 NF3nVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFTWM2OD1zN{OzJI5O Mne5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
TCCSUP NFG1SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF2MjDuUS=> MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
MGH-U3 NITxTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTV|IH7N MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
HT-1197 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K5RmlEPTB;NUOgcm0> NXXpd21KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
5637 NYXYUXlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoeyTWM2OD12NDDuUS=> NFXsS4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
35612 M1PHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\QTWM2OD1|ODDuUS=> NV\HZZZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
KU-19-19 NEi3OZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTLTWM2OD1|NjDuUS=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
LB831-BLC MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jsTWlEPTB;M{Sgcm0> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NEizPUc,OjR5OES4N|k9N2F-
UM-UC3 Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN|IH7N Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
647-V MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXGfWRKSzVyPUK3JI5O MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
HT-1376 M3XFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJzIH7N M2jmTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
J82 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDWeGVDUUN3ME2xPEBvVQ>? MnjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OES4N|koRjJ2N{i0PFM6RC:jPh?=
BFTC M2\nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvOXVNKSzVyPUG3JI5O NXrJU|k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
SCaBER MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4njWmlEPTB;MUCgcm0> M{GzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i0PFM6Lz5{NEe4OFg{QTxxYU6=
639-V MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz1TWM2OD1zMDDuUS=> NGjvNoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
RT112 M3zMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC4TWM2OD17IH7N NIDubI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
T24 NGjnTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTdibl2= NH7xcVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4OFg{QSd-MkS3PFQ5Ozl:L3G+
SW-1710 NXvSNI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnclkyUUN3ME22JI5O NY\vVpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
DSH1 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmzSFh2UUN3ME22JI5O NWfpNW86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFQ5OzlpPkK0O|g1QDN7PD;hQi=>
CAL27 NFzWOZhEgXSxeHnjbZR6KEG|c3H5 M{S2TlExNzVyIH7N NXGwdVJ3OjRiaB?= NFvWXmpl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> NXXaPYI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFU1OzBpPkK1NlA2PDNyPD;hQi=>
Detroit562 MlfGR5l1d3irY3n0fUBCe3OjeR?= NWn3UYdCOTBxNUCgcm0> NWfWXpY1OjRiaB?= Mnex[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyNUSzNEc,OjV{MEW0N|A9N2F-
FUDA M2nGPWN6fG:6aXPpeJkhSXO|YYm= NIj3flYyOC93MDDuUS=> MUSyOEBp M{W1UoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NGXKV4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
SCC25 NFfWclNEgXSxeHnjbZR6KEG|c3H5 M{GwZVExNzVyIH7N NYG2fVByOjRiaB?= Ml7Y[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 NEXGfJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKwOVQ{OCd-MkWyNFU1OzB:L3G+
HT-29 NV\kTlhWTnWwY4Tpc44hSXO|YYm= MWe1NI5O NX:5b5pYOjRiaB?= MmO3SG1UVw>? NVjU[JN[cW6mdXPl[EBIOC:JMTDhdpJme3R? Mnu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUC3PVQoRjJ3MkGwO|k1RC:jPh?=
HCT-116 MWTGeY5kfGmxbjDBd5NigQ>? NGjVb3o2OG6P NFj5T3AzPCCq NHzWPI5FVVOR NHzxcm5qdmS3Y3XkJGcxN0dzIHHydoV{fA>? NXvmOYo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVA4QTRpPkK1NlExPzl2PD;hQi=>
MGC-803 NYr5R5FLTnWwY4Tpc44hSXO|YYm= M4fwOlAvOS1zMECwJI5O NILUUY4zPCCq NYqycox1cW6mdXPld{BIOi:PIHPlcIwu[3mlbHWgZZJz\XO2 MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
MKN-28 NFz5SmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXX4T29QOC5zLUGwNFAhdk1? NVq5d4h1PzJiaB?= MVfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC4NFUoRjJ3NUmwPFA2RC:jPh?=
SGC-7901 Ml\4R4VtdCCYaXHibYxqfHliQYPzZZk> Mof4NE4yNTFyMECgcm0> M{Dl[lczKGh? MnjDbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEiwOUc,OjV3OUC4NFU9N2F-
MGC-803 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUWwMlEuOTByMDDuUS=> NVL0S|dZPzJiaB?= NIPFN3JqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M2K3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmwPFA2Lz5{NUW5NFgxPTxxYU6=
MV411 NVS2eWo3SXCxcITvd4l{KEG|c3H5 MmjGN|AwQDBxMUWwM|I2OCCwTR?= NWmxW4Q3OjRxNEivO|IhcA>? NHmzdplqdmS3Y3XzJIRwe2ViZHXw[Y5l[W62IHnu[JVkfGmxbjDv[kBieG:ydH;zbZM> MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1OVAoRjJ3OEiyOVUxRC:jPh?=
HL60 M4myeWFxd3C2b4Ppd{BCe3OjeR?= NXOwV3c6OzBxOECvNVUxNzJ3MDDuUS=> MUGyOE81QC95MjDo M{nGbYlv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=> NFjOZYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4NlU2OCd-MkW4PFI2PTB:L3G+
TC32 NX:2c2hEeUiWUzDhd5NigQ>? M1L6bJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| M4\1T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 M{XDT5FJXFNiYYPzZZk> MkHPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 MXLxTHRUKGG|c3H5 NETiS5ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz M3nYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 M{jNTpFJXFNiYYPzZZk> MmXGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M3zFO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD MUfxTHRUKGG|c3H5 NV;BToVIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| M4rwWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NVzEXIFHeUiWUzDhd5NigQ>? NYnFdm9SeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> Ml3nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MULxTHRUKGG|c3H5 MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MUDxTHRUKGG|c3H5 MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| M4jaWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NHPEOWpyUFSVIHHzd4F6 MmPTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k> M2j5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MkHQdWhVWyCjc4PhfS=> MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= M4fBO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NEXIdGNyUFSVIHHzd4F6 MkTVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB-EBc1 MX3xTHRUKGG|c3H5 MonJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= NGOx[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 Ml3tdWhVWyCjc4PhfS=> MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MnXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 M3PFUJFJXFNiYYPzZZk> MlzPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK; 

PubMed: 23418523     


Downregulation of multiple signaling pathways by ganetespib in melanoma cells.A. Cells were treated with indicated amounts of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated.

p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4; 

PubMed: 23418523     


Alterations in expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control䲧疝Ỵ疞㧀疜膉痘 

Survivin / Bcl-2 / Bcl-xl / Mcl-1; 

PubMed: 23418523     


Effect of ganetespib on the expression of antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins are indicated.

B-RAF / C-RAF / N-RAS ; 

PubMed: 23418523     


Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells.Cells were treated with indicated amounts of ganetespib for 48 h and subjected to Western blot analysis.

HER2 / p-STAT3 / BIM ; 

PubMed: 25077897     


NCI-H1975 cells were incubated with the indicated concentrations of ganetespib for 24 h. Cell lysates were analyzed by Western blotting.

CDK1 / Cyclin D1 / Cyclin B1 / p27; 

PubMed: 29717218     


Cropped Western blot images of the indicated cell cycle regulators are shown in ganetespib-treated (0–300 nM for 16 hours) BT474 and SKBR3 cells. 

c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9; 

PubMed: 29717218     


Cropped images of Western blots at the target molecular weights for the indicated apoptotic markers are shown in ganetespib-treated (0, 10, 30, 100, 300 nM for 16 hours) BT474 and SKBR3 cells. 

ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3; 

PubMed: 29717218     


Ganetespib inhibits RTK signaling in ErbB2+ breast cancer cells. BT474 and SKBR3 cells were treated with ganetespib (0, 10, 30, 100, or 300 nM) for 16 hours, followed by Western blot analysis (cropped images) of the expression and activation/phosphorylati䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖

Wee1 / p-Wee1 / Chk1 / p-Chk1; 

PubMed: 27834954     


Hsp90 inhibition degrades the G2/M checkpoint kinases Wee1 and Chk1. The cells were treated with 200 nM ganetespib and 75 μM carboplatin for 24 h followed by immunoblot analysis. Carboplatin treatment leads to the activation of Chk1, indicated by phospho—䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ

23418523 25077897 29717218 27834954
Growth inhibition assay
Cell viability ; 

PubMed: 23418523     


A. Ganetespib reduced viability. Cells were treated with varying amounts of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean±SD of three independent experiments. B. Mutational status and ganetespib IC50 of cell lines.

23418523
In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A
Smiles CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Terminated Drug: Ziv-Aflibercept|Drug: Ganetespib Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 2 2014 Phase 1
NCT02008877 Completed Drug: ganetespib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors (MPNST)|Sarcoma Sarcoma Alliance for Research through Collaboration|Synta Pharmaceuticals Corp.|United States Department of Defense December 2013 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • Answer:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Related HSP (HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID